Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | MMP8 | P22894 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 3/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473766 | 0.91 | DGAT1 (0.50) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL22473628 | 0.91 | DGAT1 (0.50) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL22473788 | 0.89 | DGAT1 (0.51) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL22473657 | 0.89 | DGAT1 (0.51) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL22473625 | 0.88 | DGAT1 (0.59) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL18751731 | 0.88 | DGAT1 (0.53) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL22473778 | 0.87 | DGAT1 (0.60) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL20999841 | 0.85 | DGAT1 (0.51) | DGAT1GBA1MMP2MMP9MMP8 | |
| SCHEMBL21118065 | 0.85 | DGAT1 (0.51) | DGAT1GBA1EPHX2 | |
| SCHEMBL18751727 | 0.84 | HSP90AB1 (0.48) | DGAT1EPHX2EP300HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787443-B2 | RAF-degrading conjugate compounds | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787443-B2 | RAF-degrading conjugate compounds | BRAF, RAF1, ARAF | DGAT1 1679/4885GBA1 833/4885MMP2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.